Add to the list of reasons not to have open heart surgery the potential use of Bayer’s (BAY) Trasylol to control bleeding. According to The Wall Street Journal "two studies published in 2006 suggested the drug doubled the risk of kidney failure/" The FDA is reviewing the drug due to the kidney issue and because" two additional studies have suggested the drug also could increase the risk of death."
The FDA has a "black box" warning on the Trasylol label. but the studies do raise that question of why the drug is on the market at all.
Maybe someone should look into this.
Douglas A. McIntyre
Find a Qualified Financial Advisor (Sponsor)
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
